Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections (Q36140657)

12 August 2017

1 reference

title

Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections (English)

1 reference

12 August 2017

3

Herbert L DuPont

1 reference

12 August 2017

Laura Gerard

1

1 reference

PubMed ID

15918778

12 August 2017

Kevin W Garey

series ordinal

2

1 reference

12 August 2017

1 April 2005

1 reference

Expert Review of Anti-infective Therapy

12 August 2017

1 reference

12 August 2017

3

1 reference

12 August 2017

2

1 reference

12 August 2017

201-211

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

12 August 2017

1 reference

Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Susceptibility to rifaximin of Vibrio cholerae strains from different geographical areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

In vitro activity of rifaximin against Helicobacter pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

In vitro activity and fecal concentration of rifaximin after oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

CXC and CC chemokine expression in inflamed and noninflamed pelvic ileal pouch tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

An outbreak of Escherichia coli O157:H7 infections among visitors to a dairy farm

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Novel roles for the AIDA adhesin from diarrheagenic Escherichia coli: cell aggregation and biofilm formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Enteroaggregative Escherichia coli: an emerging enteric pathogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Antimicrobials as potential adjunctive agents in the treatment of biofilm infection with Staphylococcus epidermidis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Penetration of rifampin through Staphylococcus epidermidis biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Effect of vancomycin and rifampicin on meticillin-resistant Staphylococcus aureus biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Therapy of travelers' diarrhea with rifaximin on various continents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Rifaximin in the treatment of chronic hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Intestinal bacterial overgrowth during chronic pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Clinical aspects and pathophysiology of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Review article: medical treatment of active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Diagnosis and management of pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Clostridium difficile--Associated diarrhea: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.201

21 January 2018

Identifiers

DOI

10.1586/14787210.3.2.201

1 reference

12 August 2017

1 reference

PubMed ID

15918778